A Phase II Study of Dasatinib Therapy in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Latest Information Update: 10 Mar 2025
At a glance
- Drugs Dasatinib (Primary) ; Dasatinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 07 Mar 2025 Status changed from active, no longer recruiting to completed.
- 14 Feb 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 31 Aug 2023 Planned End Date changed from 1 Dec 2031 to 7 Dec 2029.